ABSTRACT-The effects of harmaline on tryptophan-induced 5-hydroxytryptamine (5-HT) syndrome and body temperature changes in pargyline-pretreated rats were investigated. When administered i.p. 60 min after pargyline treatment (50 mg/kg, i.p.), tryptophan, at 100 mg/kg but not 10 mg/kg, induced the 5-HT syndrome. Tryptophan at 100 mg/kg also produced hypothermia followed by hyperthermia in pargylinepretreated rats. Administration of harmaline (10 mg/kg, i.p.) 30 min after pargyline not only potentiated the 100 mg/kg tryptophan-induced 5-HT syndrome and body temperature changes, but also produced the syndrome following administration of 10 mg/kg tryptophan in pargyline-pretreated rats. In contrast, when administered 30 min before pargyline, 10 mg/kg harmaline completely suppressed the syndrome and body temperature changes caused by 100 mg/kg tryptophan. Tryptophan (100 mg/kg, i.p.) administration significantly increased 5-HT levels and decreased 5-hydroxyindole acetic acid levels and 5-HT turnover in the brain of pargyline-pretreated rats. Harmaline administration 30 min after pargyline did not significantly affect the tryptophan-induced changes in 5-HT levels and 5-HT turnover, whereas when administered 30 min before pargyline, harmaline significantly blocked the effect of tryptophan. These results suggest that mechanisms underlying the inhibitory action of harmaline on the tryptophan-induced 5-HT syndrome and body temperature changes in pargyline-pretreated rats differ from those by which harmaline potentiates the effects of tryptophan.
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The 5-hydroxytryptamine (5-HT)-mediated behavioral syndrome is widely accepted as an index to measure serotonergic function in the brain and to test rapidly drugs capable of interacting with the central 5-HT systems (1). The syndrome includes tremor, forepaw treading, hindlimb abduction, head weaving, flat body posture and ambulation, and it is known to be accompanied by body temperature change (2, 3) . Accumulating evidence demonstrates that the 5-HT syndrome reflects predominantly the activity of 5-HT-mediated synapses.
The 5-HT precursors, L-tryptophan and 5-hydroxytryptophan (5-HTP), produce the syndrome in animals pretreated with a monoamine oxidase (MAO) inhibitor, and the effects are blocked by a tryptophan hydroxylase inhibitor or a L-aromatic amino acid decarboxylase inhibitor (4) . In contrast, the preferential 5-HT uptake blocker clomipramine (5) and the 5-HT releaser fenfluramine reportedly produce or potentiate the 5-HT syndrome (6, 7) . It has been suggested that the 5-HT1A-receptor subtype is mainly involved in the 5-HT syndrome, since 5-HT1A-receptor agonists induce the syndrome and the effects can be attenuated by 5-HT1A-receptor antagonists (8, 9) .
Harmala alkaloids and their (3-carboline analogs exhibit multiple pharmacological properties in vitro and in vivo. In vitro studies have shown that these alkaloids interact reversibly with 5-HT receptors and benzodiazepine receptors (10) (11) (12) (13) (14) in the brain, inhibit the activity of monoamine oxidase-A (MAO-A) (15 -17) and modulate the release and reuptake of monoamines (18, 19) .
Moreover, harmala alkaloids are known to produce tremorogenic and 5-HT-like activities in vivo (20) (21) (22) (23) . In spite of a number of studies on harmaline and other harmala alkaloids, the actions of harmaline on the central 5-HT systems in vivo are still controversial. For example, the harmaline-induced tremor is inhibited by 5-HTP in monkeys (24, 25) , while coadministration of harmaline with 5-HTP reportedly causes a lethal convulsive myoclonic syndrome (26) . Thus, in this study, to further clarify the mechanisms underlying the action of harmaline on the central 5-HT systems activated by endogenous 5-HT, we investigated the effects of harmaline on the 5-HT syndrome and body temperature changes caused by tryptophan in pargyline-pretreated rats.
Animals
Male Wistar rats weighing 300-400 g (Japan SLC, Hamamatsu) were used in the experiments. The animals were housed in groups of 4-5 per cage (35 x 30 x 16 cm) for at least one week before starting the experiments. Housing conditions were thermostatically maintained at 24 ± 2 C with a relative humidity of 55 ± 5 010 with a 12-hr light : dark cycle (lights on: 0730-1930). Animals were given free access to food and water.
Behavioral assessment
The effect of harmaline on the tryptophan-induced 5-HT syndrome: Tryptophan (10, 100 mg/kg) was administered intraperitoneally (i.p.) at time 0. Either saline or harmaline was injected i.p. 30 or 90 min before tryptophan (i.e., 30 min before or after pargyline administration). Except for the saline-pretreated control, rats received pargyline (50 mg/kg, i.p.) 60 min before tryptophan. One hour after tryptophan administration, behavioral changes were observed for 1 min at 20-min intervals over a 2-hr period. The behavioral parameters such as head weaving, forepaw treading, hindlimb abduction and flat body posture were scored according to the method of Jacobs (27) using a ranked intensity scale (i.e., 0=absent, 1= equivocal, 2=present and 3=intense). Ambulation was measured by counting the number of times an animal entered quadrants drawn in the cage floor (35 x 30 x 16 cm).
The effect of harmaline on the (±)-8-hydroxy-dipropylaminotetraline (8-OH-DPA T)-induced 5-HT syndrome: Saline or harmaline (10 mg/kg) was injected i.p. 90 min before 8-OH-DPAT (5 mg/kg, s.c.). We chose this time schedule to compare the effects of harmaline with those observed when harmaline was administered 90 min before tryptophan injection to the pargyline-pretreated rats. Behavioral observation was started 3 min after 8-OH-DPAT injection and repeated every 3 min over a 15-min period according to Tricklebank et al. (8) . In each observation session, behavioral responses appearing during a 45-sec observation period were scored and summed over the 5 observation periods.
Measurement of body temperature
Measurement of body temperature was performed as previously described (3). In brief, immediately after scoring the behavioral responses, the rectal temperature of each rat was measured using a digital thermometer (Delta SK1250 Mc; Sato Keiryoki MFG, Co., Ltd., Tokyo) every 30 min over a 6-hr period.
Measurement of biogenic monoamines and their metabolites levels in the brain
Rats were decapitated at 3 hr after tryptophan administration when the tryptophan-induced 5-HT syndrome peaked in the pargyline-pretreated rats. The brains were rapidly removed and washed in ice-cold saline. The striatum, cortex, hypothalamus and hippocampus were dissected on an ice-cold plate and frozen in liquid nitrogen. The levels of monoamine and monoamine metabolites in these tissues were measured by a slight modification of the method described in our previous papers (28, 29) . Briefly, each tissue was homogenized in 1 ml of icecold 0.25 M HC1O4 solution containing 0.3 mg cysteine, 0.05 mg EDTA and the internal standard isoproterenol. After centrifugation at 10,000 x g at 41C for 10 min, the supernatant was filtered through an Rc-58 membrane filter (Schleicher & Schuell, Dassel, Germany) and stored at -80 C until the day of the experiments. The amount of monoamine and monoamine metabolites in the filtrate was determined by HPLC with electrochemical detection.
Drugs
The following drugs were used: pargyline HCl and harmaline HCl (Nacalai Tesque, Inc., Kyoto), DL-tryptophan (Aldrich Chem., Co., Inc., Milwaukee, WI, USA), (±)-8-hydroxy-dipropylaminotetraline HBr (8-OH-DPAT) (Sigma Chem., St. Louis, MO, USA). The drugs were dissolved in saline except for tryptophan. Tryptophan was suspended in saline containing 0.5010 carboxymethyl cellulose sodium (CMC). Drug solutions were prepared immediately before starting the experiments and injected i.p. in a constant volume of 1 ml/kg body weight. Other chemicals were purchased from commercial sources.
Statistical analyses
The data obtained in the behavioral experiments were analyzed by the Kruskal-Wallis test followed by the Mann-Whitney U-test for multiple comparisons. The neurochemical data were analyzed by one-way analysis of variance (ANOVA) followed by Dunnett's test for multiple comparison among groups. Differences with P < 0.05 were considered statistically significant. parameters of the syndrome caused by tryptophan 100 mg/kg (i.p.). Moreover, the animals administered with a low dose of tryptophan (10 mg/kg, i.p.) after pargyline did not exhibit the syndrome, but harmaline (5 and 10 mg/kg, i.p.) administration 30 min after pargyline dosedependently caused marked 5-HT syndrome in these animals ( Fig. 2) .
Effect of harmaline on the 8-OH-DPAT-induced 5-HT syndrome in rat 8-OH-DPAT (5 mg/kg, s.c.), a selective 5-HT1A-receptor agonist, also produced the 5-HT syndrome in rats. Harmaline administration (10 mg/kg, i.p.) 90 min before 8-OH-DPAT had no effect on the behavioral parameters of the syndrome (Table 1) . Effect of harmaline on body temperature changes caused by tryptophan in pargyline pretreated rats Consistent with our previous report (3), tryptophan (100 mg/kg, i.p.) administration caused hypothermia followed by hyperthermia in the pargyline-pretreated rats (Fig. 3) . Harmaline (10 mg/kg, i.p.) administration 30 min after pargyline attenuated the hypothermia and markedly potentiated the hyperthermia caused by tryptophan. In these rats, 100% mortality was observed following hyperthermia. Harmaline itself did not cause mortality in the pargyline-pretreated rats. In contrast, 10 mg/kg harmaline administration 30 min before pargyline significantly suppressed both the hypothermic and hyperthermic effects of tryptophan 100 mg/kg (Fig. 3) . Table 3 . Effect of harmaline on tryptophan (100 mg/kg)-induced changes in biogenic monoamine synthesis and turnover in rats Effect of harmaline on tryptophan-induced changes in the level of monoamines and their metabolites in pargylinepretreated rat Three hours after tryptophan 100 mg/kg-administration (when tryptophan-induced 5-HT syndrome peaked), a significant increase in 5-HT levels and a significant decrease in 5-hydroxy indole acetic acid (5-HIAA) levels were observed in all the brain regions of pargylinepretreated rats (Table 2) . These changes caused a significant decrease in the 5-HIAA/5-HT ratio (Table 3) . Moreover, a significant decrease in the levels of dopamine (DA) metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), but not DA was observed in the various brain regions except for the hippocampus following administration of tryptophan (100 mg/kg, i.p.) to the pargyline-pretreated rats (Table 2) . A significant decrease in the HVA/DA ratio was also observed in the striatum and hypothalamus of pargylinepretreated rats following the administration of tryptophan (Table 3) caused by tryptophan 100 mg/kg. Tryptophan, at 10 mg/kg, caused a significant increase in 5-HT levels in the brain of pargyline-pretreated rats, but it did not significantly change the 5-HIAA levels. Administration of harmaline (5 and 10 mg/kg) 30 min after pargyline treatment did not significantly potentiate the action of 10 mg/kg tryptophan (Fig. 4) . The present study demonstrates that harmaline produces facilitatory and inhibitory effects on the 5-HT syndrome and body temperature changes caused by tryptophan in pargyline-pretreated rats, and the appearance of these effects depended on the time of harmaline administration. Tryptophan, at 10 mg/kg, did not cause the 5-HT syndrome in pargyline-pretreated rats, but when harmaline was administered 30 min after pargyline, tryptophan markedly produced the syndrome. Moreover, harmaline potentiated the 5-HT syndrome and hyperthermia caused by 100 mg/kg tryptophan, resulting in 100% mortality in these rats. These facilitatory effects of harmaline are consistent with the data that coadministration of harmaline with 5-HTP produces a lethal convulsive myoclonic syndrome (26) .
A previous report from this laboratory demonstrated that 100 mg/kg tryptophan induces hypo-and hyperthermia, which are mediated by 5-HT1A-and 5-HT2-receptor subtypes, respectively, in pargyline-pretreated rats (3). Moreover, the 5-HT syndrome is known to be dominantly mediated by 5-HTIA-receptor stimulation (8, 9) . Taken together, harmaline-induced potentiation of the 5-HT syndrome and body temperature changes caused by tryptophan may be due to excess stimulation of 5-HT1A and 5-HT2 receptors in the brain. Nevertheless, to directly demonstrate the involvement of these receptor subtypes in the harmaline-induced potentiation requires further investigation using selective antagonists for the 5-HTIAand 5-HT2-receptor subtypes.
Harmaline is known to increase endogenous 5-HT level (30) in the brain by inhibiting MAO activity. However, harmaline potentiation of tryptophan-induced changes in behavior and body temperature does not seem to be due to an additive or synergistic increase in endogenous 5-HT level in the nerve terminals, because when administered 30 min after pargyline, harmaline did not significantly change the 5-HT level or 5-HT turnover in the brain tissue following tryptophan administration (10, 100 mg/kg). Besides the inhibition of MAO activity, harmaline reportedly inhibits high affinity uptake of 5-HT into a synaptosomal fraction prepared from various brain regions (10, 31) . Thus, it is conceivable that by inhibiting 5-HT uptake into the nerve terminals, harmaline may additively or synergistically increase the endogenous 5-HT level in the synaptic cleft following tryptophan administration, resulting in potentiation of 5-HT1A-and 5-HT2-receptor-mediated responses in rats. This idea seems to be supported by the data that harmaline did not alter the 5-HT syndrome caused by the selective 5-HT1A-receptor agonist 8-OH-DPAT. Moreover, recently we found by the in vivo microdialysis technique that the extracellular 5-HT level in the dorsal hippocampus significantly increased following systemic administration of harmaline (A.-F.Md. Abdel-Fattah et al., unpublished data).
The present results do not exclude the possible involvement of other neuronal systems. In fact, it has been reported that harmala alkaloids have affinity for benzodiazepine receptors (13) and act as a weak or partial agonist at the receptor site (14) . Moreover, diazepam can block the convulsive myoclonic syndrome caused by coadministration of harmaline and 5-HTP (26) . Thus, harmaline may potentiate the syndrome by interacting with GABAergic systems.
It is of interest to note that when harmaline was administered 30 min before pargyline, it completely suppressed the tryptophan-induced 5-HT syndrome and body temperature changes, and these inhibitory effects were accompanied by significant inhibition of tryptophan-induced changes in 5-HT levels and 5-HT turnover in the brain. Several factors may serve to explain these suppressing actions of harmaline. First, harmaline or harmaline metabolites may attenuate the 5-HT syndrome by blocking the 5-HT1A-receptor subtype. However, this does not seem to be the situation, because harmaline had no effect on the 5-HT syndrome caused by the selective 5-HT1A-receptor agonist 8-OH-DPAT as discussed above. Secondly, the different profiles in the MAO inhibition between harmaline and pargyline may explain the apparent antagonistic action of harmaline on tryptophan-induced 5-HT syndrome in rats. Harmaline reportedly produces the short-acting and reversible inhibition of MAO activity, while the inhibitory effect of pargyline on the activity is known to be long-lasting and irreversible (32, 33) . Thus, the reversible modulation of MAO by harmaline may decrease the irreversible inhibitory action of pargyline on this enzyme. This idea is supported by the data that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a competitive and reversible inhibitor of MAO-A, inhibits the increase in DA and the decrease in DOPAC and HVA concentration following pargyline administration (33) .
In conclusion, the present results suggest that mechanisms underlying the inhibitory action of harmaline on the tryptophan-induced 5-HT syndrome and body temperature changes in pargyline-pretreated rats differ from those by which harmaline potentiates the effects of tryptophan.
